• Dr. Michael Thurn resigns as Managing Director and CEO
• Sergio Duchini to assume role of Interim Executive Chair
• Global search for new CEO underway

Neurizon Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF), a clinical-stage biotech company focused on neurodegenerative diseases, has announced that Dr. Michael Thurn has resigned as Managing Director and Chief Executive Officer. Dr. Thurn will step down from his executive responsibilities on March 16, 2026 and will serve his contractual notice period until July 2026. During this transition period, he will work with the Board to ensure an orderly leadership change and remain available to support the transition activities. Dr. Thurn will continue to serve as a Non-Executive Director until the completion of his notice period. Under Dr. Thurn's leadership, the company has made significant progress, including the transition from PharmAust to Neurizon Therapeutics, progression of clinical programs, regulatory engagement, expansion of strategic partnerships, and advancement of the company's entry into the Phase 2/3 HEALEY ALS Platform Trial. Until a new CEO is appointed, Mr. Sergio Duchini will assume the role of Interim Executive Chair to ensure continuity of leadership and maintain the execution of the company's clinical and corporate development programs. Neurizon has engaged a leading global executive search firm, Coulter Partners, to support the recruitment process for a new CEO, and further updates will be provided as developments materialize.

Neurizon remains committed to advancing its clinical development programs and delivering meaningful outcomes for patients and shareholders. The company believes the foundations established across the clinical, regulatory, and strategic fronts leave it well-positioned for its next stage of growth.